Journal of Microscopy and Ultrastructure

REVIEW ARTICLE
Year
: 2020  |  Volume : 8  |  Issue : 4  |  Page : 148--151

Renin–Angiotensin system implications to COVID-19 comorbidities


Hadeel A Alsufyani1, Zienab Alrefaie2 
1 Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
2 Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Physiology, Faculty of Medicine, Cairo University, Cairo, Egypt

Correspondence Address:
Prof. Zienab Alrefaie
Department of Physiology, Faculty of Medicine, King Abdulaziz University and Department of Physiology, Faculty of Medicine, Cairo University, Cairo, Egypt

The role of the renin–angiotensin system (RAS) and its pharmacological modulators in the susceptibility and outcomes of SARS CoV-2 pandemic (COVID-19) has been much discussed recently. Angiotensin-converting enzyme type 2 (ACE2) has attracted much attention and debate in relevance to COVID-19. It not only acts as the receptor to which the SARS CoV-2 virus binds to be introduced into cells but also balances the effects of angiotensin II offering anti-inflammatory and antifibrotic protective actions to different organs. This mini-review aims to shed some light on the possible involvement of ACE2 and RAS alternate pathways in the comorbidities and clinical findings observed in COVID-19 patients.


How to cite this article:
Alsufyani HA, Alrefaie Z. Renin–Angiotensin system implications to COVID-19 comorbidities.J Microsc Ultrastruct 2020;8:148-151


How to cite this URL:
Alsufyani HA, Alrefaie Z. Renin–Angiotensin system implications to COVID-19 comorbidities. J Microsc Ultrastruct [serial online] 2020 [cited 2021 Jan 25 ];8:148-151
Available from: https://www.jmau.org/article.asp?issn=2213-879X;year=2020;volume=8;issue=4;spage=148;epage=151;aulast=Alsufyani;type=0